The use of spironolactone and eplerenone, which antagonize MR similarly in both epithelial and non-epithelial tissues, is limited mainly by the mechanism based risk for hyperkalemia, which is increased 3- to 8-fold in patients with reduced kidney function (CKD stage ≥ 3) [22, 23]. This evidence concerns the gene NR3C2 and Hyperkalemia.